Zomedica Corp. (ZOM)
USD 0.12
(-2.8%)
USD 0.12
(-2.8%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -34.52 Million USD | -102.93% |
| 2023 | -17.01 Million USD | 7.44% |
| 2022 | -18.38 Million USD | -8.64% |
| 2021 | -16.92 Million USD | 14.64% |
| 2020 | -19.82 Million USD | -19.07% |
| 2019 | -16.64 Million USD | -106.42% |
| 2018 | -8.06 Million USD | -34.13% |
| 2017 | -6.01 Million USD | -163.63% |
| 2016 | -2.28 Million USD | -5278.0% |
| 2015 | -42.4 Thousand USD | 45.27% |
| 2014 | -77.49 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -491 Thousand USD | 90.65% |
| 2024 Q4 | -22.4 Million USD | -4463.34% |
| 2024 Q1 | -6.38 Million USD | -127.31% |
| 2024 Q2 | -5.24 Million USD | 17.79% |
| 2024 FY | -34.52 Million USD | -102.93% |
| 2023 FY | -17.01 Million USD | 7.44% |
| 2023 Q3 | -4.99 Million USD | 5.27% |
| 2023 Q2 | -5.27 Million USD | -33.93% |
| 2023 Q1 | -3.93 Million USD | -19.67% |
| 2023 Q4 | -2.8 Million USD | 43.76% |
| 2022 Q2 | -4.71 Million USD | -16.69% |
| 2022 Q4 | -3.28 Million USD | 48.15% |
| 2022 FY | -18.38 Million USD | -8.64% |
| 2022 Q1 | -4.03 Million USD | 3.27% |
| 2022 Q3 | -6.34 Million USD | -34.71% |
| 2021 FY | -16.92 Million USD | 14.64% |
| 2021 Q2 | -5.3 Million USD | -116.6% |
| 2021 Q1 | -2.45 Million USD | 14.23% |
| 2021 Q4 | -4.17 Million USD | 16.2% |
| 2021 Q3 | -4.97 Million USD | 6.18% |
| 2020 Q2 | -2.4 Million USD | 79.41% |
| 2020 FY | -19.82 Million USD | -19.07% |
| 2020 Q4 | -2.85 Million USD | -0.4% |
| 2020 Q3 | -2.84 Million USD | -18.35% |
| 2020 Q1 | -11.67 Million USD | -38.65% |
| 2019 Q1 | -2.17 Million USD | 15.29% |
| 2019 FY | -16.64 Million USD | -106.42% |
| 2019 Q4 | -8.42 Million USD | -340.86% |
| 2019 Q3 | -1.91 Million USD | 53.91% |
| 2019 Q2 | -4.14 Million USD | -90.87% |
| 2018 Q1 | -1.83 Million USD | 38.38% |
| 2018 Q3 | -2.08 Million USD | -30.99% |
| 2018 Q4 | -2.56 Million USD | -23.19% |
| 2018 FY | -8.06 Million USD | -34.13% |
| 2018 Q2 | -1.58 Million USD | 13.33% |
| 2017 Q1 | -15.55 Thousand USD | 34.84% |
| 2017 Q3 | -1.04 Million USD | 2.1% |
| 2017 Q2 | -1.06 Million USD | -6742.74% |
| 2017 Q4 | -2.97 Million USD | -185.38% |
| 2017 FY | -6.01 Million USD | -163.63% |
| 2016 Q1 | -15.6 Thousand USD | -77.77% |
| 2016 Q4 | -23.87 Thousand USD | -400.88% |
| 2016 Q3 | -4766.69 USD | 57.23% |
| 2016 FY | -2.28 Million USD | -5278.0% |
| 2016 Q2 | -11.14 Thousand USD | 28.59% |
| 2015 Q2 | -7895.27 USD | -34.8% |
| 2015 Q4 | -8779.16 USD | 20.97% |
| 2015 Q3 | -11.1 Thousand USD | -40.7% |
| 2015 FY | -42.4 Thousand USD | 45.27% |
| 2015 Q1 | -5857.02 USD | 88.46% |
| 2014 Q2 | -14.5 Thousand USD | 0.0% |
| 2014 Q4 | -50.74 Thousand USD | -640.24% |
| 2014 FY | -77.49 Thousand USD | 0.0% |
| 2014 Q3 | -6855.44 USD | 52.75% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| China Pharma Holdings, Inc. | -3.07 Million USD | -1021.502% |
| cbdMD, Inc. | -22.93 Million USD | -50.53% |
| cbdMD, Inc. | -22.93 Million USD | -50.53% |